Chosa Oncology

Executive Summary

Chosa Oncology is a Swedish precision oncology company founded in 2018, focused on developing its proprietary Platin-DRP® gene expression test to predict patient response to platinum-based chemotherapies in solid tumors. By identifying which patients are most likely to benefit from platinum agents, the test aims to reduce ineffective treatments and associated toxicities, enabling more personalized cancer care. The company operates in the biomarker-driven diagnostics space, targeting a significant unmet need in oncology. As a private, early-stage company with limited public information, Chosa Oncology's progress hinges on clinical validation, regulatory approvals, and commercialization partnerships. Its technology has the potential to improve treatment outcomes and reduce healthcare costs by guiding therapy decisions for a broad patient population.

Upcoming Catalysts (preview)

• Q3 2026Publication of Clinical Validation Study for Platin-DRP®60% success
• Q4 2026CE Marking or Regulatory Submission in Europe50% success
• Q1 2027Strategic Partnership with a Diagnostic or Pharma Company40% success